Dapirolizumab pegol
Also known as: anti-CD40L Fab-PEG, CDP7657, Dapirolizumab pegol, DZS-SLE, RG786
Source Dapirolizumab pegol at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dapirolizumab pegol is an investigational PEGylated Fab' antibody fragment that blocks CD40 ligand (CD40L). It is being studied as a biologic therapy for systemic lupus erythematosus (SLE), aiming to reduce disease activity in patients whose symptoms persist despite standard care.
Mechanism of Action
The molecule binds CD40L, preventing its interaction with CD40 on B cells, antigen‑presenting cells and platelets. By interrupting CD40‑CD40L signaling, it dampens B‑cell activation, antibody production, and inflammatory cytokine release, thereby modulating the autoimmune cascade characteristic of SLE.
What the Research Shows
Early phase I work (2017) showed that repeated intravenous dosing was well tolerated and produced modest improvements in composite lupus activity scores. A phase 2 trial (2021) reported clinical and immunologic gains versus placebo, but the pre‑specified dose‑response model was not met. The phase 3 PHOENYCS GO study (2026) enrolled 321 patients and demonstrated a statistically significant higher BICLA response at 48 weeks (50% vs 35%; p=0.011). Pharmacokinetic modelling from the phase 2b trial confirmed dose‑proportional exposure and a positive exposure‑response relationship for achieving BICLA response.
Reported Benefits
Evidence from the phase 3 trial indicates that dapirolizumab pegol can increase the proportion of patients achieving a clinically meaningful BICLA response compared with placebo, suggesting a reduction in disease activity. Earlier studies also observed improvements in disease activity indices and favorable changes in blood transcriptomic signatures, supporting its potential as an additional therapeutic option for SLE.
Limitations of the Evidence
The phase 2 study failed to meet its primary dose‑response objective, and the absolute benefit in the phase 3 trial was modest (14% absolute difference). Long‑term efficacy and durability after treatment cessation remain uncertain, as response rates declined after drug withdrawal in phase 2. The drug is still investigational, with no regulatory approval for SLE or other indications.
Safety Considerations
Treatment‑emergent adverse events occurred in 83% of dapirolizumab pegol recipients versus 75% on placebo; serious events were slightly lower (10% vs 15%). Notable risks included hypersensitivity reactions (3%), serious infections (4% vs 6% placebo), a single myocardial infarction, and one death from sepsis. Phase 1 data reported no serious adverse events, and overall events were described as mild to moderate and transient.
How It Is Administered
In clinical trials the drug was administered intravenously, typically 24 mg/kg every four weeks, added to standard‑of‑care therapy. Subcutaneous administration is listed as a possible route, but trial data focus on the intravenous regimen. The formulation is a PEGylated Fab' fragment designed for extended half‑life.
Routes of Administration
Goals & Uses
- Reduction of lupus flaresAutoimmune/InflammatoryModerate
- Rheumatoid arthritisAutoimmune DiseaseLow
- Reduction of autoantibody titers (anti-dsDNA)Biomarker/SerologicalModerate
- Reduction of SLE disease activityAutoimmune/InflammatoryModerate
- Steroid-sparing effect in SLEAutoimmune/InflammatoryLow
- Systemic lupus erythematosusAutoimmune DiseaseModerate
- Treatment of lupus nephritisRenal/AutoimmuneLow
Contraindications
- Hypersensitivity to dapirolizumab pegol or PEGAllergyHigh
- Known hypersensitivity to dapirolizumab pegol or PEGImmunologicHigh
- Active serious infectionsInfectiousHigh
- Active tuberculosisInfectiousHigh
Adverse Effects
- NasopharyngitisInfectiousCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Thromboembolic eventsCardiovascularRare
- Infections (upper respiratory, urinary tract)InfectiousCommon
- Infusion‑related reactionsGeneralCommon
- Serious infectionsInfectiousUncommon
- InfectionsImmunologicUncommon
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- Live vaccinesHigh
- Other immunosuppressants (mycophenolate, azathioprine, cyclophosphamide)Moderate
- Immunosuppressive agentsModerate
- CorticosteroidsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with history of recurrent serious infectionsInfectiousRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
- Renal impairment (severe)RenalRelative
Regulatory Status
- European UnionInvestigationalNot authorized by EMA.
- United StatesInvestigationalNo FDA approval; clinical trials ongoing or discontinued.
- United KingdomInvestigationalNot approved by MHRA.
Development halted after phase II due to safety concerns; not approved in any major jurisdiction.
Evidence & Sources
- Journal ArticleModerateClowse MEB, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateFurie RA, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleUngraded2022-01-01T00:00:00.000000Z
- Journal ArticleModerateChamberlain C, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateAcharya C, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateNiebel D, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is dapirolizumab pegol?
It is a PEGylated Fab' antibody fragment that specifically binds CD40 ligand, blocking the CD40‑CD40L interaction that drives B‑cell activation and inflammation in lupus.
Has dapirolizumab pegol been approved for lupus?
No. The compound remains investigational; it has completed phase 2 and phase 3 trials but has not received regulatory approval for systemic lupus erythematosus or any other condition.
What were the main safety concerns in the trials?
Common adverse events included mild to moderate reactions; serious concerns were hypersensitivity (3% of treated patients), serious infections (4%), one myocardial infarction, and one death related to sepsis. Overall serious event rates were similar or lower than placebo.
How does the drug compare to existing lupus therapies?
In the phase 3 study, dapirolizumab pegol produced a higher BICLA response rate than placebo when added to standard therapy, indicating added benefit beyond existing immunosuppressants, though the absolute improvement was modest.
Is the drug given by injection or infusion?
Clinical studies used intravenous infusion every four weeks; subcutaneous administration is mentioned as a potential route, but trial evidence relates to the IV schedule.
What is Dapirolizumab pegol?
Dapirolizumab pegol is an investigational PEGylated Fab' antibody fragment that blocks CD40 ligand (CD40L). It is being studied as a biologic therapy for systemic lupus erythematosus (SLE), aiming to reduce disease activity in patients whose symptoms persist despite standard care.
What is Dapirolizumab pegol used for?
Dapirolizumab pegol is educationally associated with: Reduction of lupus flares, Rheumatoid arthritis, Reduction of autoantibody titers (anti-dsDNA), Reduction of SLE disease activity, Steroid-sparing effect in SLE, Systemic lupus erythematosus, Treatment of lupus nephritis. Educational only — not medical advice.
How is Dapirolizumab pegol administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Dapirolizumab pegol?
Reported adverse effects include: Nasopharyngitis, Headache, Thromboembolic events, Infections (upper respiratory, urinary tract), Infusion‑related reactions, Serious infections, Infections, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dapirolizumab pegol?
Recorded contraindications: Hypersensitivity to dapirolizumab pegol or PEG, Known hypersensitivity to dapirolizumab pegol or PEG, Active serious infections, Active tuberculosis. Consult a qualified clinician before use.